Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men

Figures & data

Table I.  Baseline characteristics of participants

	Control group (n = 23)	Treated group (n = 25)	P values
Age (yr)	63.1 ± 7.7	63.2 ± 8.5	NS
Body mass index (kg/m^2)	27.2 ± 2.04	27.4 ± 3.01	NS
Serum testosterone (ng/dL)	310 ± 37	301 ± 32	NS
Serum estradiol (pg/mL)	20.9 ± 11.3	19.5 ± 9.9	NS
Lumbar density (g/cm^2)	1.187 ± 0.194	1.198 ± 0.153	NS
T score	−0.59 ± 0.97	−0.37 ± 1.23	NS
Femoral density (g/cm^2)	0.973 ± 0.172	0.969 ± 0.122	NS
T score	−0.87 ± 0.89	−0.63 ± 0.91	NS

Data are expressed as the mean ±SD.

NS, not significant; P, values by unpaired t-test.

Table II.  Hormonal levels before and after 12 months of testosterone therapy

	Control group		Treated group
	Before	After	Before	After
Testosterone (ng/dL)	310 ± 37	299 ± 58	301 ± 32	471 ± 107*
17-β Estradiol (pg/mL)	20.9 ± 11.3	20.1 ± 12.0	19.5 ± 9.9	26.4 ± 9.3*

*p < 0.01, compared to change in placebo-treated group by unpaired t-test.

Figure 1. Mean (±SD) lumbar and femoral bone mineral density (BMD) at baseline and after testosterone treatment. At the end of the study, there was a difference statistically significant in lumbar BMD between both groups. *P < 0.05 compared whit baseline, by paired t test analysis. **P < 0.05 between groups, by unpaired t test.